Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16419778 | 0.96 | CA12 (0.46) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL15037004 | 0.86 | CA12 (0.54) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL16419757 | 0.82 | CA12 (0.53) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL16419788 | 0.81 | CA12 (0.47) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL15805959 | 0.80 | CA1 (0.49) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL1236314 | 0.79 | CA12 (0.48) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL1236245 | 0.78 | CA12 (0.47) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL15036907 | 0.78 | CYP1A1 (0.41) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL16169740 | 0.76 | CA12 (0.48) | CA1CA2CA12CA9CYP1A1 | |
| SCHEMBL29713682 | 0.75 | CA12 (0.47) | CA1CA2CA12CA9CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469616-B2 | Cyclic compounds and methods of making and using the same | CELLCEUTIX CORPORATION (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2013090185-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | POLYMEDIX, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MUC1, TLR3, ALG1 | CA1 1067/4885CA2 1405/4885CA12 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.